Evidence map›Paper›PMID 27107948›Full record

ArticleBioorganic & medicinal chemistry letters2016

Synthesis of a stable and orally bioavailable englerin analogue.

David M Fash, Cody J Peer, Zhenwu Li, Ian J Talisman, Sima Hayavi, Florian J Sulzmaier, Joe W Ramos, Carole Sourbier, Leonard Neckers, W Douglas Figg and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Natural products targeting cancer cell dependency.The Journal of antibiotics · 2021
    Review
  4. Article
  5. Review
  6. Review
  7. Englerins: A Comprehensive Review.Journal of natural products · 2017
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

David M FashDepartment of Chemistry, University of Hawaii at Manoa, 2545 McCarthy Mall, Honolulu, HI 96822, United States.
Cody J PeerGenitourinary Malignancies Branch, National Cancer Institute, Frederick, MD 21702, United States.
Zhenwu LiDepartment of Chemistry, University of Hawaii at Manoa, 2545 McCarthy Mall, Honolulu, HI 96822, United States.
Ian J TalismanDepartment of Chemistry, University of Hawaii at Manoa, 2545 McCarthy Mall, Honolulu, HI 96822, United States.
Sima HayaviDevelopmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702, United States.
Florian J SulzmaierThe University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI 96813, United States.
Joe W RamosThe University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI 96813, United States.
Carole SourbierUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, United States.
Leonard NeckersUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, United States.
W Douglas FiggGenitourinary Malignancies Branch, National Cancer Institute, Frederick, MD 21702, United States.
John A BeutlerMolecular Targets Laboratory, National Cancer Institute, Frederick, MD 21702, United States. Electronic address: beutlerj@mail.nih.gov.
William J ChainDepartment of Chemistry, University of Hawaii at Manoa, 2545 McCarthy Mall, Honolulu, HI 96822, United States; The University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI 96813, United States. Electronic address: wchain@udel.edu.

Funding

This renovation project will create over 1455 sq. ft. of state- of-the-art reseaP20GM104316 · NIGMS · UNIVERSITY OF DELAWARE · PI SCHMITZ, KARL ROBERT · 2014 to 2024
$26.8M
Development of Natural Product Leads as Anticancer TherapeuticsZIABC011470 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BEUTLER, JOHN · 2012 to 2025
$7.8M
Pilot Research Subproject ProgramP30GM110758 · NIGMS · UNIVERSITY OF DELAWARE · PI BEEBE, THOMAS PAUL · 2014 to 2018
$5.8M
Molecular Design of Advanced BiomaterialsP20GM103541 · NIGMS · UNIVERSITY OF DELAWARE · PI POLENOVA, TATYANA · 2012 to 2012
$2.1M
Carbonyls to Cancer TherapeuticsR01CA163287 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CHAIN, WILLIAM JOHN · 2013 to 2016
$1.1M
Q-Exactive Orbitrap LC-MC/MS SystemS10OD016267 · OD · UNIVERSITY OF DELAWARE · PI JOHNSTON, MURRAY V · 2013 to 2013
$573k
Intramural NIH HHS ZIA BC011470NCI NIH HHS R01 CA163287NIGMS NIH HHS P20 GM103541NIGMS NIH HHS P20 GM104316NIGMS NIH HHS P30 GM110758NIH HHS S10 OD016267
6 · The paper itself

Abstract

Synthesis of analogues of englerin A with a reduced propensity for hydrolysis of the glycolate moiety led to a compound which possessed the renal cancer cell selectivity of the parent and was orally bioavailable in mice.

Indexed as

Administration, OralAnimalsAntineoplastic AgentsBiological AvailabilityCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceMolecular StructureRatsSesquiterpenes, GuaianeStructure-Activity RelationshipAntineoplastic Agentsenglerin ASesquiterpenes, GuaianeBioavailabilityCancerEnglerinsSesquiterpenes

Identifiers

PMID27107948
PMCPMC4862412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.